Search

Displaying results 2961 - 2970 of 10000 in total
  1. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285]. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.

  2. Drug

    Opium

    go.drugbank.com/drugs/DB11130
    ApprovedIllicit

    in the category of isoquinolines. … There is some legal production of opium in different countries for the obtention of alkaloids by extraction.[L1766]

  3. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.

  4. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. … FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species.

  5. Drug

    Anisindione

    go.drugbank.com/drugs/DB01125
    Approved

    Anisindione is a synthetic anticoagulant and an indanedione derivative. … II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver.

  6. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349] … [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity.

    Synonyms: enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor
  7. Drug

    Iolopride I-123

    go.drugbank.com/drugs/DB20028
    Experimental

    The usage of the INN stem '-pride' in the name indicates that Iolopride I-123 is a sulpiride derivative and analogue. Iolopride I-123 has a monoisotopic molecular weight of 400.06 Da.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  9. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

    Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamine
  10. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    However, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step … Higher doses of araC cannot be used to overcome this limitation due to bone marrow toxicity resulting from rapid activation in that tissue.